Market Research Outlook on Post-Operative Pain-Pipeline Review, H2 2016

Post-Operative Pain-Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Post-Operative Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Operative Pain and features dormant and discontinued projects.

To view the table of contents and know more details please visit Post-Operative Pain-Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Post-Operative Pain
- The report reviews pipeline therapeutics for Post-Operative Pain by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Post-Operative Pain therapeutics and enlists all their major and minor projects
- The report reviews latest news related to pipeline therapeutics for Post-Operative Pain

Reasons to buy

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Operative Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

AcelRx Pharmaceuticals, Inc. Adynxx, Inc. AngioChem Inc. AskAt Inc. Boehringer Ingelheim GmbH Cara Therapeutics, Inc. Colby Pharmaceutical Company Cytogel Pharma, LLC Dompe Farmaceutici S.p.A. DURECT Corporation Echo Pharmaceuticals B.V. Fujimoto Pharmaceutical Corporation Galleon Pharmaceuticals Grunenthal GmbH GW Pharmaceuticals Plc Heron Therapeutics, Inc. Immupharma Plc Innocoll AG INSYS Therapeutics, Inc. Laboratorios Del Dr. Esteve S.A. Lipocure Ltd. Liquidia Technologies, Inc. Medtronic plc Orbis Biosciences, Inc. Orion Oyj Pacira Pharmaceuticals, Inc. PainReform Ltd. Pharmazz, Inc. PhytoHealth Corporation Proteus SA Recro Pharma, Inc. Relmada Therapeutics, Inc. Serina Therapeutics, Inc. SteadyMed Therapeutics, Inc. Takeda Pharmaceutical Company Limited The Medicines Company Trevena, Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###